Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?

The Lancet Infectious Diseases

Volumn 17, Issue 12, 2017, Pages e429-e433

  Kunkel, Amber ^a   Furin, Jennifer ^b   Cohen, Ted ^a  

^a YALE UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; LINEZOLID; PRETOMANID; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

BACTERIAL CHROMOSOME; DRUG EFFECT; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE POLICY; HUMAN; MORTALITY RATE; PRIORITY JOURNAL; REVIEW; SPUTUM CULTURE; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS CONTROL; COMBINATION DRUG THERAPY;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS;

EID: 85019851458     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30299-2     Document Type: Review

References (52)

1. WHO. Global tuberculosis report 2016, 2016, World Health Organization, Geneva.
2. Zignol, M, Dean, AS, Falzon, D, et al. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med 375 (2016), 1081–1089.
3. Dheda, K, Gumbo, T, Maartens, G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 5 (2017), 291–360.
4. Falzon, D, Gandhi, N, Migliori, GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 42 (2013), 156–168.
5. Pietersen, E, Ignatius, E, Streicher, EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 383 (2014), 1230–1239.
6. Dheda, K, Migliori, GB, The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. Lancet 379 (2012), 773–775.
7. WHO. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance, 2013, World Health Organization, Geneva.
8. Conradie F, Diacon AH, Everitt D, et al. The Nix-TB trial of pretomanid, bedaquiline, and linezolid to treat XDR-TB. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 13–16, 2017. 80LB.
9. Diacon, AH, Pym, A, Grobusch, M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360 (2009), 2397–2405.
10. Diacon, AH, Pym, A, Grobusch, MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371 (2014), 723–732.
11. Pym, AS, Diacon, AH, Tang, SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 47 (2016), 564–574.
12. Guglielmetti, L, Le Dû, D, Jachym, M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 60 (2015), 188–194.
13. Ndjeka, N, Conradie, F, Schnippel, K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 19 (2015), 979–985.
14. Guglielmetti, L, Jaspard, M, Le Dû, D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J, 49, 2017, 1601799.
15. Cegielski, JP, Dalton, T, Yagui, M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 59 (2014), 1049–1063.
16. Furin, J, Brigden, G, Lessem, E, Rich, M, Vaughan, L, Lynch, S, Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis. Emerg Infect Dis, 22, 2016, e151430.
17. Diacon, AH, Pym, A, Grobusch, MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371 (2014), 723–732.
18. WHO. Report of the Guideline Development Group Meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis: a review of available evidence (2016), 2017, World Health Organization, Geneva.
19. Horsburgh, CR Jr, Haxaire-Theeuwes, M, Lienhardt, C, et al. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. Int J Tuberc Lung Dis 17 (2013), 146–152.
20. Dheda, K, Esmail, A, Limberis, J, Maartens, G, Selected questions and controversies about bedaquiline: a view from the field. Int J Tuberc Lung Dis 20:suppl 1 (2016), S24–S32.
21. Bloemberg, GV, Keller, PM, Stucki, D, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 373 (2015), 1986–1988.
22. Huitric, E, Verhasselt, P, Koul, A, Andries, K, Hoffner, S, Andersson, DI, Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 54 (2010), 1022–1028.
23. Salfinger, M, Migliori, GB, Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending. Eur Respir J 45 (2015), 317–321.
24. Kunkel, A, Cobelens, FG, Cohen, T, Tradeoffs in introduction policies for the anti-tuberculosis drug bedaquiline: a model-based analysis. PLoS Med, 13, 2016, e1002142.
25. Jain, A, TB institute warns against use of new drug. The Hindu, Jan 9, 2017.
26. Dharmadhikari, AS, Mphahlele, M, Venter, K, et al. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 18 (2014), 1019–1025.
27. Riley, RL, Mills, CC, Nyka, W, et al. Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. Am J Epidemiol 142 (1995), 3–14.
28. Behr, MA, Warren, SA, Salamon, H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 353 (1999), 444–449.
29. Styblo, K, Epidemiology of tuberculosis: selected papers, 1991, Royal Netherlands Tuberculosis Foundation (KNCV), The Hague.
30. Tostmann, A, Kik, SV, Kalisvaart, NA, et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis 47 (2008), 1135–1142.
31. Arnold, A, Witney, AA, Vergnano, S, et al. XDR-TB transmission in London: case management and contact tracing investigation assisted by early whole genome sequencing. J Infect 73 (2016), 210–218.
32. Klopper, M, Warren, RM, Hayes, C, et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis 19 (2013), 449–455.
33. Wang, F, Shao, L, Fan, X, et al. Evolution and transmission patterns of extensively drug-resistant tuberculosis in China. Antimicrob Agents Chemother 59 (2015), 818–825.
34. Shah, NS, Auld, SC, Brust, JC, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med 376 (2017), 243–253.
35. Dheda, K, Limberis, JD, Pietersen, E, et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med 5 (2017), 269–281.
36. Adams, S, Ehrlich, R, Baatjies, R, et al. Incidence of occupational latent tuberculosis infection in South African healthcare workers. Eur Respir J 45 (2015), 1364–1373.
37. O'Donnell, MR, Jarand, J, Loveday, M, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med 153 (2010), 516–522.
38. No authors listedStreptomycin treatment of pulmonary tuberculosis. Br Med J 2 (1948), 769–782.
39. No authors listedTreatment of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J 2 (1952), 735–746.
40. Gegia, M, Winters, N, Benedetti, A, van Soolingen, D, Menzies, D, Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis 17 (2017), 223–234.
41. McLeay, SC, Vis, P, van Heeswijk, RP, Green, B, Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother 58 (2014), 5315–5324.
42. Ndjeka N. Incorporation of bedaquiline in the South African national TB programme. Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 22–25, 2016.
43. Diacon, AH, Dawson, R, von Groote-Bidlingmaier, F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 191 (2015), 943–953.
44. Hartkoorn, RC, Uplekar, S, Cole, ST, Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58 (2014), 2979–2981.
45. Reed, C, Mason, L, Cox, H, Seaworth, B, Lessem, E, Furin, J, Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis, 15, 2015, 1131.
46. Cohen, J, Simpler, safer treatment hailed as ‘breakthrough’ against drug-resistant TB. Science Magazine, Feb 15, 2017 http://www.sciencemag.org/news/2017/02/simpler-safer-treatment-hailed-breakthrough-against-drug-resistant-tb (accessed April 3, 2017).
47. Murray, S, Mendel, C, Spigelman, M, TB Alliance regimen development for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 20 (2016), 38–41.
48. Eldholm, V, Balloux, F, Antimicrobial resistance in Mycobacterium tuberculosis: the odd one out. Trends Microbiol 24 (2016), 637–648.
49. Wilson, BA, Garud, NR, Feder, AF, Assaf, ZJ, Pennings, PS, The population genetics of drug resistance evolution in natural populations of viral, bacterial and eukaryotic pathogens. Mol Ecol 25 (2016), 42–66.
50. Rinder, H, Mieskes, KT, Löscher, T, Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 5 (2001), 339–345.
51. RESIST-TB. Drug-resistant tuberculosis clinical trials progress report. http://www.resisttb.org/?page_id=1602 (accessed Jan 26, 2017).
52. Wollenberg, KR, Desjardins, CA, Zalutskaya, A, et al. Whole-genome sequencing of Mycobacterium tuberculosis provides insight into the evolution and genetic composition of drug-resistant tuberculosis in Belarus. J Clin Microbiol 55 (2016), 457–469.